MASI Stock Recent News

The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Masimo (MASI) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $1.32 per share a year ago.

Here is how Masimo (MASI) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year.

Masimo (MASI) collaborates with UCHealth to boost patient care by combining its latest virtual care technologies with UCHealth's clinical expertise and telehealth innovations.

Masimo's core segment in Professional Healthcare could have support into a multi-year growth based on current growth of Unrecognized Contract Value growth. Expansion into the consumer space is a logical extension to leverage its core tech and segment growth. Initially, higher cost could be paid off over the future scale-up of product offering and sale channel growth.

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo's (MASI) R&D activities raise optimism about the stock.

Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Masimo (MASI) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MASI crossed above the 200-day moving average, suggesting a long-term bullish trend.

Bob Chapek, a nearly three-decade Disney veteran who was ousted in 2022 as the media company's CEO, has been appointed to the board of directors of medical tech firm Masimo. The move comes during a dramatic series of events involving Masimo and Apple.